Gilead and Kite are plunking down big cash to get into the anti-BCMA CAR-T game. The pair will shell out $225 million in cash upfront and $100 million in equity to Arcellx, Kite announced Friday morning, to develop the biotech’s lead CAR-T program together. Kite will handle commercialization and co-development…
...
News Ticker
- [ March 25, 2023 ] Senior Electrical Engineer – Tecan – Morgan Hill, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] AD, Translational – Tenaya Therapeutics, Inc. – South San Francisco, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Clinical Research Coordinator – Genetics – PAVIR – Palo Alto, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Genomics Translational Research Senior Scientist – Bristol Myers Squibb – Redwood City, CA San Francisco Biotech Jobs
- [ March 25, 2023 ] Principal Bioinformatics Scientist – Genentech – San Francisco, CA San Francisco Biotech Jobs
Copyright © 2022 Biotech Networks, LLC
